True Vision MN LLC Takes $2.33 Million Position in iShares Biotechnology ETF $IBB

True Vision MN LLC bought a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,791 shares of the financial services provider’s stock, valued at approximately $2,328,000. iShares Biotechnology ETF accounts for 1.2% of True Vision MN LLC’s investment portfolio, making the stock its 21st biggest holding.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new position in shares of iShares Biotechnology ETF in the 2nd quarter valued at $25,000. Ashton Thomas Securities LLC acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter valued at about $36,000. Parkside Financial Bank & Trust increased its stake in iShares Biotechnology ETF by 48.6% in the third quarter. Parkside Financial Bank & Trust now owns 266 shares of the financial services provider’s stock valued at $38,000 after acquiring an additional 87 shares during the period. Close Asset Management Ltd increased its stake in iShares Biotechnology ETF by 25.5% in the third quarter. Close Asset Management Ltd now owns 345 shares of the financial services provider’s stock valued at $50,000 after acquiring an additional 70 shares during the period. Finally, Founders Financial Alliance LLC raised its position in iShares Biotechnology ETF by 605.7% in the third quarter. Founders Financial Alliance LLC now owns 374 shares of the financial services provider’s stock worth $54,000 after purchasing an additional 321 shares in the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of IBB opened at $160.41 on Friday. The company has a 50-day moving average price of $171.17 and a two-hundred day moving average price of $164.06. iShares Biotechnology ETF has a 12 month low of $107.43 and a 12 month high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 20th. Investors of record on Tuesday, March 17th were given a dividend of $0.1218 per share. This represents a $0.49 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Tuesday, March 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.